2nd GPCRs-Targeted Drug Discovery Summit Europe

Europe is experiencing a renaissance in GPCR-targeted drug discovery. The unprecedented commercial success of GLP-1 receptor agonists in obesity has reignited investment, innovation, and clinical exploration across the GPCR space. With major deals such as Eli Lilly’s $1.3 billion collaboration to advance small-molecule GPCR therapeutics using AI- and ML-powered platforms, momentum is building fast, making 2025 a pivotal year to be part of this rapidly evolving field.

Returning as the only meeting dedicated exclusively to GPCR drug discovery and development in Europe, the 2nd Annual GPCR-Targeted Drug Discovery Summit Europe brings together the brightest minds in biopharma to translate this momentum into actionable strategies.

From expanding pipelines in cardiometabolic disease, neuroscience, oncology, and inflammation, to tackling biased signalling and optimising pharmacological modulation, this summit delivers the breadth and depth you need to progress differentiated, best-in-class GPCR-targeting drugs.

Whether you’re looking to identify new targets, enhance your discovery toolkit, or forge critical collaborations, this is your opportunity to stay ahead of the curve as biopharma redefines the druggable paradigm with next-generation GPCR therapeutics.